Clinical Score Identifies Th2-Driven Endotype in Bullous Pemphigoid

Molecular Stratification in Autoimmune Blistering Disease

Bullous pemphigoid remains the most prevalent autoimmune subepidermal blistering disorder, primarily affecting elderly populations and imposing a substantial burden on patient quality of life [1]. While current European guidelines provide a standardized framework for management using systemic or topical corticosteroids, the disease is characterized by marked clinical heterogeneity that frequently complicates therapeutic decision-making [2]. Up to 20% of patients present without classic bullae, instead exhibiting varied features such as urticarial plaques or eczematous lesions [1]. Recent investigations into type 2 inflammation (a specific immune response involving Th2 cells and eosinophils) have prompted the use of targeted biologics in refractory cases, suggesting that distinct molecular drivers may exist within the broader patient population [3]. Despite these advancements, the lack of accessible biomarkers to guide individualized therapy remains a significant hurdle in clinical practice [4]. A new study now examines whether standard clinical scoring can serve as a reliable surrogate for these underlying molecular pathways.

Clinical Phenotyping and Patient Demographics

The cohort study enrolled 143 hospitalized patients with bullous pemphigoid at a tertiary center between January 2024 and June 2025 to investigate the relationship between clinical presentation and molecular drivers. The study population had a mean age of 73.9 years, and 58.7% of the participants (84 of 143) were male. To better understand the clinical heterogeneity of the disease, the researchers utilized the Bullous Pemphigoid Disease Area Index (BPDAI), a validated tool used to quantify skin involvement and disease activity. Specifically, they focused on the urticaria/erythema subscore, which measures the extent of non-bullous inflammatory lesions. Patients were stratified into two distinct groups based on a threshold of 5 on the BPDAI urticaria/erythema subscore, a cutoff derived from the first quartile of the subscore distribution (the value below which the lowest 25% of the data points fall). Those with a subscore of 5 or greater were classified as having inflammatory bullous pemphigoid (I-BP), while those with a subscore of less than 5 were categorized as having pauci-inflammatory bullous pemphigoid (PI-BP), a term referring to cases with minimal urticarial or erythematous involvement. Within the total cohort, 108 patients (75.5%) met the criteria for I-BP, while 35 patients (24.5%) were classified as PI-BP. The clinical profiles of these two groups revealed significant differences in patient characteristics and symptom burden. Compared to the PI-BP group, patients in the I-BP group were younger and experienced more severe pruritus. This suggests that a higher burden of urticarial and erythematous lesions, as captured by the BPDAI subscore, is not only a marker of skin involvement but also correlates with more intense subjective symptoms and distinct demographic patterns within the bullous pemphigoid population.

Laboratory Markers and Hospitalization Outcomes

The clinical distinction between inflammatory bullous pemphigoid (I-BP) and pauci-inflammatory bullous pemphigoid (PI-BP) is mirrored by significant differences in systemic inflammatory markers. Patients in the I-BP group exhibited significantly elevated peripheral eosinophil counts of 0.6 ×10^9/L, whereas those in the PI-BP group had counts of 0.2 ×10^9/L (P=0.001). This peripheral eosinophilia, a hallmark of type 2 immune responses, was accompanied by a marked disparity in cytokine profiles. Specifically, serum interleukin-5 (IL-5) levels were significantly higher in the I-BP group at 52.5 pg/mL, compared to only 3.9 pg/mL in the PI-BP group (P=0.007). These findings suggest that the urticaria/erythema subscore of the Bullous Pemphigoid Disease Area Index (BPDAI) effectively identifies a subset of patients with a more pronounced Th2-driven systemic inflammatory state, characterized by the recruitment and activation of eosinophils. The increased inflammatory burden associated with the I-BP phenotype translates into greater clinical complexity and higher resource utilization. Despite receiving more intensive therapy, patients with I-BP required a longer median hospital stay of 8 days, while those in the PI-BP group had a median stay of 7 days (P=0.029). This discrepancy highlights a clinical paradox where the more aggressive treatment regimens administered to I-BP patients were not sufficient to equalize the duration of hospitalization compared to their less inflammatory counterparts. For the practicing clinician, these data indicate that a high BPDAI urticaria/erythema subscore at presentation may serve as a prognostic indicator for a more protracted clinical course and a potentially more refractory response to standard interventions, necessitating closer monitoring and perhaps earlier consideration of targeted biological therapies.

Proteomic Profiling and Th2 Signaling

To elucidate the molecular mechanisms driving these clinical differences, the researchers conducted serum proteomic profiling using the Olink Target 96 Inflammation panel, a high-throughput technology that measures 92 protein biomarkers associated with inflammatory pathways. This analysis was performed in a representative subset of 37 patients from the larger cohort. The proteomic analysis identified eight differentially expressed proteins between the inflammatory bullous pemphigoid (I-BP) and pauci-inflammatory bullous pemphigoid (PI-BP) groups. Specifically, the researchers found that interleukin-13 (IL-13), thymic stromal lymphopoietin (TSLP), oncostatin M (OSM), and monocyte chemoattractant protein-4 (MCP-4) were significantly upregulated in the I-BP group. These proteins are central mediators of type 2 inflammation, which is often associated with allergic responses and tissue eosinophilia. The study further established a direct link between these molecular markers and clinical presentation. IL-13, TSLP, OSM, and MCP-4 showed a positive correlation with the Bullous Pemphigoid Disease Area Index (BPDAI) urticaria/erythema subscore (P<0.05). Notably, these same proteins did not correlate with the BPDAI erosions/blisters subscore, suggesting that this specific cytokine profile drives the inflammatory, non-bullous features of the disease rather than the blistering process itself. Among the identified biomarkers, IL-13 demonstrated the highest diagnostic accuracy for the I-BP endotype, with an Area Under the Curve (AUC) of 0.87. This high AUC (a statistical measure where 1.0 represents a perfect test and 0.5 represents random chance) indicates that IL-13 is a highly reliable indicator for identifying patients with the Th2-driven inflammatory phenotype, potentially allowing clinicians to use the BPDAI urticaria/erythema subscore as a bedside surrogate for complex molecular profiling.

Implications for Targeted Therapy

The identification of specific molecular drivers in bullous pemphigoid suggests a path toward more precise management of the disease. Through functional enrichment analysis (a statistical method used to identify biological pathways that are overrepresented in a protein dataset), the researchers confirmed differential activation of type 2 inflammation in the inflammatory bullous pemphigoid group. This group, defined by a Bullous Pemphigoid Disease Area Index (BPDAI) urticaria/erythema subscore of 5 or greater, also showed differential activation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway, which is a primary intracellular mechanism for mediating cytokine responses. These findings indicate that the clinical presentation of extensive redness and hives is not merely a surface-level variation but is rooted in a distinct Th2-ligand/JAK-STAT-signaling circuit. For the practicing clinician, these results provide a biological rationale for using the BPDAI urticaria/erythema subscore as a clinical surrogate for a Th2-driven molecular endotype (a disease subtype defined by a specific functional or biological mechanism). Because the subscore correlates with elevated levels of interleukin-13 and other type 2 cytokines, it may help identify patients who are less likely to respond to standard corticosteroid tapers alone. The study suggests that patients with a high inflammatory burden may benefit from a stratified treatment approach involving targeted type 2 immunotherapies or JAK inhibitors. While these findings require further prospective validation, they offer a framework for selecting advanced therapies based on the bedside BPDAI assessment rather than relying solely on generalized treatment protocols.

References

1. Feliciani C, Joly P, Jonkman MF, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. British Journal of Dermatology. 2015. doi:10.1111/bjd.13717

2. Borradori L, Beek NV, Feliciani C, et al. UpdatedS2K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). Journal of the European Academy of Dermatology and Venereology. 2022. doi:10.1111/jdv.18220

3. Olbrich H, Sadik CD, Ludwig RJ, Thaçi D, Boch K. Dupilumab in Inflammatory Skin Diseases: A Systematic Review. Biomolecules. 2023. doi:10.3390/biom13040634

4. Sadik C, Rashid H, Hammers C, et al. Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial.. JAMA dermatology. 2022. doi:10.1001/jamadermatol.2022.1156